Martin Storr, MD
Affiliations: | Medicine | University of Calgary, Calgary, Alberta, Canada |
Google:
"Martin Storr"Mean distance: 106866
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Brierley SM, Greenwood-Van Meerveld B, Sarnelli G, et al. (2022) Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome. Nature Reviews. Gastroenterology & Hepatology |
| Szymaszkiewicz A, Włodarczyk J, Wasilewski A, et al. (2020) Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. Naunyn-Schmiedeberg's Archives of Pharmacology |
| Kienzl M, Storr M, Schicho R. (2020) Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases. Clinical and Translational Gastroenterology |
| Fabisiak A, Włodarczyk M, Fabisiak N, et al. (2019) Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases : Jgld. 28: 473-481 |
| Salaga M, Binienda A, Tichkule RB, et al. (2019) Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43]. European Journal of Pharmacology. 172656 |
| Szymaszkiewicz A, Malkiewicz A, Storr M, et al. (2019) The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. Journal of Physiology and Pharmacology : An Official Journal of the Polish Physiological Society. 70 |
| Szymaszkiewicz A, Storr M, Fichna J, et al. (2018) Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society. e13526 |
| Salaga M, Binienda A, Tichkule RB, et al. (2018) The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. European Journal of Pharmacology |
| Szymaszkiewicz A, Zielinska M, Li K, et al. (2018) Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice. Naunyn-Schmiedeberg's Archives of Pharmacology |
| Binienda A, Storr M, Fichna J, et al. (2017) Efficacy and safety of serotonin receptor ligands in the treatment of irritable bowel syndrome: a review. Current Drug Targets |